Isis hits another new high on SMA data
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals, whose stock has quadrupled during the past year, reached a new high of $59 per share on 21 February after the company reported interim data from two separate clinical trials for its spinal muscular atrophy (SMA) drug ISIS-SMNRx.